Eli Lilly reported mixed quarterly results, with sales of its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soaring, but lower realized prices overshadowing gains.
Demand for Eli Lilly’s incretin drugs has outpaced supply in the US over the past year. The company’s quarter earnings topped estimates, but fell short on sales due to lower prices. Zepbound underperformed expectations, while Mounjaro saw stronger growth.
Eli Lilly’s fiscal 2025 profit guidance remains unchanged, with a range of $22.05-$23.55 per share. The company also plans to report late-stage data on its next-generation obesity drug retatrutide later this year.
In the fourth quarter, Eli Lilly posted adjusted earnings of $5.32 per share, beating expectations of $4.95. Revenue rose 45% to $13.53 billion, driven by strong demand for Mounjaro. However, Zepbound’s sales fell short, at $1.91 billion.
The mixed results are a departure from Eli Lilly’s preliminary January results, which disappointed investors. Despite this, the company’s sales guidance remains unchanged, with estimates of $58-$61 billion for fiscal 2025.
Source: https://www.cnbc.com/2025/02/06/eli-lilly-lly-earnings-q4-2024.html